Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Update on C-RAD delivery of its advanced surface tracking solution to Swedish Cancer Center Nya Karolinska Solna

Posted on: 13 Dec 17

C-RAD announced in August that a contract to supply Nya Karolinska Solna (NKS) and Södersjukhuset in Stockholm, Sweden with its latest SIGRT (Surface Image Guided Radiation Therapy) solution was signed with Elekta Instruments AB, the Swedish subsidiary of Elekta AB (publ). C-RAD wants to give an update on this project.

C-RAD is aware of the information that has been published by Elekta on December 12, 2017 with regards to the Letter of Intent on the supply of cancer care equipment to the center Nya Karolinska Solna and Södersjukhuset in Stockholm.

The background is a public tender that was awarded to Elekta in 2016 to equip the radiation therapy department of NKS and Södersjukhuset with Elekta radiation therapy equipment and 3rd party products. The customer, Stockholm County Council, specifically requested C-RAD`s cutting edge surface tracking systems based on the products Sentinel 4DCT and Catalyst HD, to be included in the contract. Therefore C-RAD acts as a sub supplier to Elekta. C-RAD has a close cooperation with all major vendors for linear accelerator. Therefore, regardless of who will be the chosen supplier in this project, it is our goal that the customer will retain their initial request for the C-RAD advanced surface tracking solution as a part of the delivery.

C-RAD is in close dialogue with the customer and with Elekta to determine the steps forward. As soon as new and relevant information related to C-RAD’s supply of the surface tracking systems is available, C-RAD will provide an update to the market.

The contract has a total value of 21 MSEK for C-RAD, whereas a minor part has been delivered and C-RAD received payment.

“Independent from the most recent development C-RAD is very committed to continue working with the clinical customer and to provide this prestigious center with the latest surface tracking technology.” says Tim Thurn, CEO and President of C-RAD AB,

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email

This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 08:30 CET on December 13, 2017.


Last updated on: 14/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.